Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 334.82M P/E - EPS this Y 27.80% Ern Qtrly Grth -
Income -130.41M Forward P/E -2.40 EPS next Y 1.60% 50D Avg Chg -2.00%
Sales 5.76M PEG - EPS past 5Y - 200D Avg Chg -6.00%
Dividend N/A Price/Book 1.37 EPS next 5Y - 52W High Chg -38.00%
Recommedations 1.60 Quick Ratio 6.42 Shares Outstanding 61.37M 52W Low Chg 54.00%
Insider Own 0.71% ROA -27.99% Shares Float 34.90M Beta 1.44
Inst Own 89.57% ROE -59.51% Shares Shorted/Prior 2.79M/2.86M Price 6.78
Gross Margin 100.00% Profit Margin - Avg. Volume 149,540 Target Price 15.83
Oper. Margin -695.25% Earnings Date - Volume 83,496 Change -1.74%
About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Monte Rosa Therapeutics, Inc. News
08/28/24 Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
08/24/24 Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth
08/19/24 Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
08/08/24 Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
08/08/24 Monte Rosa Therapeutics: Q2 Earnings Snapshot
08/08/24 Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
07/08/24 Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
06/27/24 Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
06/14/24 Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
06/04/24 Institutional investors own a significant stake of 40% in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)
05/30/24 Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
05/30/24 Monte Rosa Therapeutics Announces Leadership Team Promotions
05/21/24 Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
05/16/24 Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
05/15/24 Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
05/10/24 Monte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
05/09/24 Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
05/02/24 Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
04/10/24 Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why
04/04/24 Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
GLUE Chatroom

User Image Fullratio Posted - 7 hours ago

Healthcare sector stocks with high revenue growth in Q2 2024 (TTM): $ADAP $GLUE $ABVC

User Image Himel92 Posted - 2 days ago

The Last month Performance for $GLUE Opening Price: $3.78 Closing Price: $5.63 Highest Price: $7.05 Lowest Price: $3.52 Percentage Change: 48.94% Data analyst: AITX

User Image Fullratio Posted - 3 days ago

Healthcare sector stocks with high gross profit growth in Q2 2024 (TTM): $ADAP $ALVO $GLUE

User Image Ohyaythejoy Posted - 08/28/24

$GLUE see pure fucking trash fuck this company....

User Image insidemoney Posted - 08/27/24

$GLUE Monte Rosa Therapeutics, Inc. 14-Day RSI: 70.2 % from 52-Week Low: +185.7% % from 52-Week High: -21.2% Open Interest: 2,109 % Change: +5% Put/Call Ratio: 0.06 % Change: +561.1%

User Image Ferrari360 Posted - 08/27/24

$GLUE looks like glue is heading to $29

User Image StockInvest_us Posted - 08/26/24

Signal alert: $GLUE - PivotPoint bottom https://stockinvest.us/l/fiaYO3e8Xy

User Image MartyCat Posted - 08/26/24

$GLUE another 10% today!

User Image EmmelineStives Posted - 08/24/24

$FTEL $FVCB $GAUZ $GHSI $GLUE Thanks to Stocktwits for sharing this amazing website!

User Image _www_larval_com_ Posted - 08/22/24

$VMAR -5%[-32%] $GOVX -4%[-12%] $FFIE -3%[117%] $GLUE -3%[-14%] $GDC 3%[99%] most notable movement into the final minutes of trading.

User Image Ohyaythejoy Posted - 08/22/24

$GLUE look its still fucking garbage..... go figure.....

User Image Windy007 Posted - 08/22/24

$GLUE Looks like someone pumped GLUE the last couple of days and took the gain today.

User Image insidemoney Posted - 08/22/24

Options Spikes (Aug 21) $LGF.A Lions Gate Entertainment Class A % Change -1.60% Trade Count 21 Total National 18.8 K 90 Day Average 5.6 K Calls 15.6 K Puts 3.2 K $GLUE Monte Rosa Therapeutics % Change 11.80% Trade Count 11 Total National 10.7 K 90 Day Average 3.2 K Calls 10.6 K Puts 185

User Image PenkeTrading Posted - 08/22/24

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Monte Rosa Therapeutics Inc. Is that bullish or bearish? $GLUE #GLUE #nasdaq #tradingsignals #technicalanalysis

User Image dixiebull Posted - 08/21/24

$NEON see if 5 can hold now for 5.50 and 6 $DNA gave a nice push to 9.37, see if 9.25 holds for a move to 10 and 10.50 $EOSE hit 2.43, we want 2.35 to hold for a break of 2.50 for 3 $GLUE rising channel to 6.81, see if 6.50 can hold for break of 7 for 8 $MGNI almost got 14 but see if 13.50 holds for a break of 14 to 15

User Image S_Franconi Posted - 08/20/24

$GLUE

User Image S_Franconi Posted - 08/20/24

$GLUE Very nice!

User Image BioTuesdays Posted - 08/19/24

Monte Rosa Therapeutics announced that the first participant has been dosed in its Phase 1 healthy volunteer study evaluating MRT-6160, a VAV1-directed MGB being developed for systemic and neurological autoimmune diseases $GLUE https://biotuesdays.com/2024/08/19/first-participant-dosed-in-monte-rosas-phase-1-study-of-mrt-6160-for-autoimmune-disease/

User Image Stock_Titan Posted - 08/19/24

$GLUE Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study https://www.stocktitan.net/news/GLUE/monte-rosa-therapeutics-announces-first-participants-dosed-in-mrt-t35yj0gxfy3y.html

User Image S_Franconi Posted - 08/13/24

$GLUE Great day!

User Image Stock_Titan Posted - 08/08/24

$GLUE Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update https://www.stocktitan.net/news/GLUE/monte-rosa-therapeutics-announces-second-quarter-2024-financial-rhdoo3zxsdyh.html

User Image Ohyaythejoy Posted - 1 month ago

$GLUE these guys are the worst.....

User Image NVDAMillionaire Posted - 07/31/24

$GLUE GLUE: A Promising Molecular Glue Degrader Platform with Significant Potential http://beyondspx.com/2024/07/31/glue-a-promising-molecular-glue-degrader-platform-with-significant-potential/

User Image Ohyaythejoy Posted - 07/29/24

$GLUE wow look its pure trash still....

User Image Harlyboy Posted - 07/25/24

$GLUE could see data any day now

User Image S_Franconi Posted - 07/18/24

$GLUE Added.

User Image RamenLives Posted - 07/18/24

$GLUE i think my 4.50 order may fill

User Image S_Franconi Posted - 07/16/24

$GLUE I think there is a very good chance $GLUE could go early buyout.

User Image S_Franconi Posted - 07/16/24

$GLUE Nice day here.

User Image Ohyaythejoy Posted - 07/11/24

$HOOD $GLUE $NXTC shits either about to explode or implode seems like charts are tightening.......

Analyst Ratings
Wells Fargo Overweight Aug 12, 24
Piper Sandler Overweight Jun 28, 24
Wedbush Outperform May 22, 24
Wedbush Outperform Feb 15, 24
JP Morgan Overweight Oct 19, 23
Credit Suisse Neutral Aug 11, 23
Credit Suisse Neutral May 12, 23
Credit Suisse Neutral Mar 17, 23
Wells Fargo Overweight Jan 3, 23